Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis

BACKGROUND: The indication for treatment of type 1 diabetes(T1D) with the sodium–glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i...

Descripción completa

Detalles Bibliográficos
Autores principales: Stougaard, Elisabeth B, Kristensen, Peter L, Kielgast, Urd, Andersen, Henrik U, Hamid, Yasmin, Gæde, Peter H, Søndergaard, Esben, Dørflinger, Gry H, Fjeldborg, Karen K, Hansen, Klavs W, Thomsen, Henrik H, Al-Imar, Thuraya M.J., Røder, Michael, Sridhar, Vikas S, Cherney, David, Rossing, Peter, Persson, Frederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585567/
https://www.ncbi.nlm.nih.gov/pubmed/36262089
http://dx.doi.org/10.1177/14791641221130043
Descripción
Sumario:BACKGROUND: The indication for treatment of type 1 diabetes(T1D) with the sodium–glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark. METHODS: Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate. RESULTS: From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0–29.0) months. The incidence of DKA was zero%. CONCLUSION: In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.

Ejemplares similares